B. Fautrel, G. Cukierman, J. Joubert, C. Laurendeau, J. Gourmelen et al., Characteristics and management of rheumatoid arthritis in France: Analysis of a representative French national claims database resulting in an estimated prevalence of

. 35%, Joint Bone Spine, vol.8, pp.461-463, 2016.

J. S. Smolen, D. Aletaha, and I. B. Mcinnes, The Lancet, vol.388, pp.2023-2061, 2016.

C. M. Deighton, D. J. Walker, I. D. Griffiths, and D. F. Roberts, The contribution of H LA to rheumatoid arthritis, Clin Genet, vol.36, pp.178-82, 2008.

I. B. Mcinnes and G. Schett, The Pathogenesis of Rheumatoid Arthritis, N Engl J Med, vol.365, pp.2205-2224, 2011.

P. Stastny, Association of the B-Cell Alloantigen DRw4 with Rheumatoid Arthritis, N Engl J Med, vol.298, pp.869-71, 1978.

P. K. Gregersen, J. Silver, and R. J. Winchester, The shared epitope hypothesis. an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis, Arthritis Rheum, vol.30, pp.1205-1218, 1987.

C. Richez, T. Barnetche, T. Schaeverbeke, and M. Truchetet, La polyarthrite rhumatoïde : une physiopathologie mieux connue ?, Rev Rhum Monogr, vol.84, pp.311-318, 2017.

X. Puéchal, I. Fajac, T. Bienvenu, N. Desmazes-dufeu, D. Hubert et al., Increased frequency of cystic fibrosis ?F508 mutation in bronchiectasis associated with rheumatoid arthritis, Eur Respir J, vol.13, pp.1281-1288, 1999.

T. E. Scott, R. A. Wise, M. C. Hochberg, and F. M. Wigley, HLA-DR4 and pulmonary dysfunction in rheumatoid arthritis, Am J Med, vol.82, pp.765-71, 1987.

G. J. Tobón, P. Youinou, and A. Saraux, The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis, J Autoimmun, vol.35, pp.10-14, 2010.

V. Goëb, N. Klemmer, L. Loët, X. Vittecoq, and O. , Tabac et maladies systémiques, Rev Rhum, vol.74, pp.726-757, 2007.

L. Klareskog, P. Stolt, K. Lundberg, H. Källberg, C. Bengtsson et al., A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination, Arthritis Rheum, vol.54, pp.38-46, 2006.

A. Van-der-helm-van-mil, K. N. Verpoort, S. Le-cessie, T. Huizinga, R. De-vries et al., The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide, Arthritis Rheum, vol.56, pp.425-457, 2007.

B. Nyhall-wahlin, Smoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis, Ann Rheum Dis, vol.65, pp.601-607, 2006.

H. Canhao, A. M. Rodrigues, A. F. Mourao, F. Martins, M. J. Santos et al., Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis, Rheumatology, vol.51, pp.2020-2026, 2012.

S. Saevarsdottir, S. Wedrén, M. Seddighzadeh, C. Bengtsson, A. Wesley et al., Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: Observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Reg, Arthritis Rheum, vol.63, pp.26-36, 2011.

H. Källberg, B. Ding, L. Padyukov, C. Bengtsson, J. Rönnelid et al., Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke, Ann Rheum Dis, vol.70, pp.508-519, 2011.

Y. Maeda and K. Takeda, Host-microbiota interactions in rheumatoid arthritis, Exp Mol Med, p.51, 2019.

A. Pianta, S. Arvikar, K. Strle, E. E. Drouin, Q. Wang et al., Evidence for Immune Relevance of Prevotella copri, a Gut Microbe, in Patients with Rheumatoid Arthritis, Arthritis Rheumatol Hoboken NJ, vol.69, pp.964-75, 2017.

J. Morel, B. Fautrel, and D. Loeuille, Polyarthrite rhumatoïde : physiopathologie, épidémiologie et imagerie -Rheumatoid arthritis: physiopathology, epidemiology and imaging patterns, vol.5, 2005.

J. A. Sparks and K. H. Costenbader, Rheumatoid arthritis in 2017: Protective dietary and hormonal factors, Nat Rev Rheumatol, vol.14, pp.71-73, 2018.

, On The Occurrence Of A Factor In Human Serum Activating The Specific Agglutintion of Sheep Blood Corpuscles, APMIS, vol.115, pp.422-460, 2007.

M. M. Newkirk, Rheumatoid factors: what do they tell us?, J Rheumatol, vol.29, pp.2034-2074, 2002.

G. A. Schellekens, B. A. Jong, . De, F. H. Hoogen, P. Van-den et al., Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies, J Clin Invest, vol.101, pp.273-81, 1998.

C. Hua and B. Combe, Les nouveaux critères de classification ACR/EULAR 2010 pour un diagnostic plus précoce de la polyarthrite rhumatoïde, Rev Rhum Monogr, vol.84, pp.337-379, 2017.

X. Dong, Z. Zheng, Y. Zhai, Y. Zheng, J. Ding et al., ACPA mediates the interplay between innate and adaptive immunity in rheumatoid arthritis, Autoimmun Rev, vol.17, pp.845-53, 2018.

J. Shi, R. Knevel, P. Suwannalai, M. P. Van-der-linden, G. Janssen et al., Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage, Proc Natl Acad Sci U S A, vol.108, pp.17372-17379, 2011.

M. Gioud-paquet, M. Auvinet, T. Raffin, P. Girard, M. Bouvier et al., IgM rheumatoid factor (RF), IgA RF, IgE RF, and IgG RF detected by ELISA in rheumatoid arthritis, Ann Rheum Dis, vol.46, pp.65-71, 1987.

I. Teitsson, IgA Rheumatoid Factor as Predictor of Disease Activity, Scand J Rheumatol, vol.17, pp.233-240, 1988.

A. J. Macpherson, K. D. Mccoy, F. Johansen, and P. Brandtzaeg, The immune geography of IgA induction and function, Mucosal Immunol, vol.1, pp.11-22, 2008.

, Expression cloning of a human Fc receptor for IgA, J Exp Med, vol.172, pp.1665-72, 1990.

E. Aleyd, M. Al, C. W. Tuk, C. J. Van-der-laken, and M. Van-egmond, IgA Complexes in Plasma and Synovial Fluid of Patients with Rheumatoid Arthritis Induce Neutrophil Extracellular Traps via Fc?RI, J Immunol, vol.197, pp.4552-4561, 2016.

G. Maury, C. Pilette, and Y. Sibille, Immunité sécrétoire des voies respiratoires, Rev Mal Respir, vol.12, 2003.

J. Rangel-moreno, L. Hartson, C. Navarro, M. Gaxiola, M. Selman et al., Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis, J Clin Invest, vol.116, pp.3183-94, 2006.

V. C. Willis, M. K. Demoruelle, L. A. Derber, C. J. Chartier-logan, M. C. Parish et al., Sputum Autoantibodies in Patients With Established Rheumatoid Arthritis and Subjects at Risk of Future Clinically Apparent Disease, Arthritis Rheum, vol.65, pp.2545-54, 2013.

M. K. Demoruelle, M. H. Weisman, P. L. Simonian, D. A. Lynch, P. B. Sachs et al., Airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity, Arthritis Rheum, vol.64, pp.1756-61, 2012.

G. P. Harvey, T. R. Fitzsimmons, A. Dhamarpatni, C. Marchant, D. R. Haynes et al., Expression of peptidylarginine deiminase-2 and -4, citrullinated proteins and anti-citrullinated protein antibodies in human gingiva, J Periodontal Res, vol.48, pp.252-61, 2013.

E. Berglin, T. Johansson, U. Sundin, E. Jidell, G. Wadell et al., Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset, Ann Rheum Dis, vol.65, pp.453-461, 2006.

E. Lindqvist, K. Eberhardt, K. Bendtzen, D. Heinegard, and T. Saxne, Prognostic laboratory markers of joint damage in rheumatoid arthritis, Ann Rheum Dis, vol.64, pp.196-201, 2005.

D. A. Houssien, T. Jónsson, and E. Davi, Rheumatoid factor isotypes, disease activity and the outcome of rheumatoid arthritis: Comparative effects of different antigens, Scand J Rheumatol, vol.27, pp.46-53, 1998.

N. Courvoisier, M. Dougados, A. Cantagrel, P. Goupille, O. Meyer et al., Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study, Arthritis Res Ther, vol.10, p.106, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00375615

X. L. Loët, M. Brazier, O. Mejjad, P. Boumier, A. Daragon et al., Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: A simple model of prediction from a conservatively treated community-based inception cohort, Arthritis Care Res, vol.62, pp.1739-1786, 2010.

M. Brink, M. Hansson, L. Mathsson-alm, P. Wijayatunga, M. K. Verheul et al., Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis, Arthritis Res Ther, vol.18, 2016.

S. Rantapää-dahlqvist, B. De-jong, E. Berglin, G. Hallmans, G. Wadell et al., Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis: Anti-CCP Antibody and IgA-RF Predict RA, Arthritis Rheum, vol.48, pp.2741-2750, 2003.

T. Jónsson, S. Arinbjarnarson, J. Thorsteinsson, K. Steinsson, Á. J. Geirsson et al., Raised IgA Rheumatoid Factor (RF) but not IgM RF or IgG RF is Associated with Extra-articular Manifestations in Rheumatoid Arthritis, Scand J Rheumatol, vol.24, pp.372-377, 1995.

C. Jorgensen, M. C. Legouffe, C. Bologna, J. Brochier, and J. Sany, IgA isotype rheumatoid factor in rheumatoid arthritis: clinical implications, Clin Exp Rheumatol, vol.14, pp.301-305, 1996.

B. Másdóttir, T. Jónsson, V. Manfreðsdóttir, A. Víkingsson, Á. Brekkan et al., Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis, Rheumatology, vol.39, pp.1202-1207, 2000.

A. L. Olson, J. J. Swigris, D. B. Sprunger, A. Fischer, E. R. Fernandez-perez et al., Rheumatoid arthritis-interstitial lung disease-associated mortality, Am J Respir Crit Care Med, vol.183, pp.372-380, 2011.

H. Lioté, Manifestations respiratoires spécifiques de la polyarthrite rhumatoïde : « le poumon rhumatoïde, Rev Mal Respir, vol.16, 2008.

J. T. Giles, S. K. Danoff, J. Sokolove, C. A. Wagner, R. Winchester et al., Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease, Ann Rheum Dis, vol.73, pp.1487-94, 2014.

T. Bongartz, C. Nannini, Y. F. Medina-velasquez, S. J. Achenbach, C. S. Crowson et al., Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study, Arthritis Rheum, vol.62, pp.1583-91, 2010.

P. Ellman and R. E. Ball, Rheumatoid Disease" with Joint and Pulmonary Manifestations, Br Med J, vol.2, pp.816-836, 1948.

P. Juge and P. Dieudé, Pneumopathies interstitielles diffuses au cours de la polyarthrite rhumatoïde, Rev Rhum Monogr, vol.85, pp.153-162, 2018.

D. Makrygiannakis, M. Hermansson, A. Ulfgren, A. P. Nicholas, A. Zendman et al., Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells, Ann Rheum Dis, vol.67, pp.1488-92, 2008.

J. J. Solomon, J. H. Chung, G. P. Cosgrove, M. K. Demoruelle, and E. R. Fernandez-perez,

A. Fischer, Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease, Eur Respir J, vol.47, pp.588-96, 2016.

N. Singh, J. Varghese, B. R. England, J. J. Solomon, K. Michaud et al., Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: A systematic literature review and meta-analysis, Semin Arthritis Rheum, vol.49, pp.358-65, 2019.

J. A. Zamora-legoff, M. L. Krause, C. S. Crowson, J. H. Ryu, and E. L. Matteson, Patterns of interstitial lung disease and mortality in rheumatoid arthritis, Rheumatol Oxf Engl, vol.56, pp.344-50, 2017.

V. Cottin, B. Crestani, D. Valeyre, B. Wallaert, J. Cadranel et al.,

, Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique. Élaborées par le centre national de référence et les centres de compétence pour les maladies pulmonaires rares sous l'égide de la Société de pneumologie de langue française, Rev Mal Respir, vol.30, pp.879-902, 2013.

P. Juge, J. S. Lee, E. Ebstein, H. Furukawa, E. Dobrinskikh et al.,

, Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease, N Engl J Med, vol.379, pp.2209-2228, 2018.

K. K. Brown and . Rheumatoid-lung-disease, Proc Am Thorac Soc, vol.4, pp.443-451, 2007.

E. Bendstrup, J. Møller, S. Kronborg-white, T. S. Prior, and C. Hyldgaard, Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians, J Clin Med, vol.8, p.2038, 2019.

S. Rantapää-dahlqvist, B. De-jong, E. Berglin, G. Hallmans, G. Wadell et al., Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis: Anti-CCP Antibody and IgA-RF Predict RA, Arthritis Rheum, vol.48, pp.2741-2750, 2003.

T. Jónsson, J. Thorsteinsson, A. Kolbeinsson, E. Jónasdóttir, N. Sigfússon et al., Population study of the importance of rheumatoid factor isotypes in adults, Ann Rheum Dis, vol.51, pp.863-871, 1992.

K. B. Eberhardt, B. Svensson, L. Truedsson, and F. A. Wollheim, The occurrence of rheumatoid factor isotypes in early definite rheumatoid arthritis--no relationship with erosions or disease activity, J Rheumatol, vol.15, pp.1070-1074, 1988.

E. J. Bernstein, R. G. Barr, J. Austin, S. M. Kawut, G. Raghu et al.,

, Rheumatoid arthritis-associated autoantibodies and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis, Thorax, vol.71, pp.1082-90, 2016.

G. Raghu, M. Remy-jardin, J. L. Myers, L. Richeldi, C. J. Ryerson et al., Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline, Am J Respir Crit Care Med, vol.198, pp.44-68, 2018.

P. U. Dalal and D. M. Hansell, High-resolution computed tomography of the lungs: the borderlands of normality, Eur Radiol, vol.16, pp.771-80, 2006.

L. Lantuejoul, E. Grangette, A. Nerot, S. Quetant, E. Reymond et al.,

, Apports de la classification ATS/ERS/JRS/ALAT 2018 au diagnostic de la fibrose pulmonaire idiopathique, J Imag Diagn Interv, vol.2, pp.217-244, 2019.

D. A. Lynch, J. Austin, J. C. Hogg, P. A. Grenier, H. Kauczor et al.,

. Ct-definable, Subtypes of Chronic Obstructive Pulmonary Disease: A Statement of the Fleischner Society, Radiology, vol.277, pp.192-205, 2015.

, and by The ERS Executive Committee, International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias: This Joint Statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, vol.165, pp.277-304, 2001.

A. Abhishek, G. Nakafero, C. Kuo, C. Mallen, W. Zhang et al.,

, Rheumatoid arthritis and excess mortality: down but not out. A primary care cohort study using data from Clinical Practice Research Datalink, Rheumatology, vol.57, pp.977-81, 2018.

R. Castellanos-moreira, S. C. Rodríguez-garcía, M. J. Gomara, V. Ruiz-esquide, A. Cuervo et al., Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease, Ann Rheum Dis, vol.79, pp.587-94, 2020.

B. Ley, C. J. Ryerson, E. Vittinghoff, J. H. Ryu, S. Tomassetti et al., A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis, Ann Intern Med, vol.156, p.684, 2012.

T. J. Doyle, A. S. Patel, H. Hatabu, M. Nishino, G. Wu et al., Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers, Am J Respir Crit Care Med, vol.191, pp.1403-1415, 2015.

L. B. Kelmenson, B. D. Wagner, B. K. Mcnair, A. Frazer-abel, and M. K. Demoruelle,

D. T. Bergstedt, Timing of Elevations of Autoantibody Isotypes Prior to Diagnosis of Rheumatoid Arthritis, Arthritis Rheumatol, vol.72, pp.251-61, 2020.

J. R. Kolfenbach, K. D. Deane, L. A. Derber, C. O'donnell, M. H. Weisman et al., A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA, Arthritis Rheum, vol.61, pp.1735-1777, 2009.

J. Zhu, Y. Zhou, X. Chen, and J. Li, A Metaanalysis of the Increased Risk of Rheumatoid Arthritis-related Pulmonary Disease as a Result of Serum Anticitrullinated Protein Antibody Positivity, J Rheumatol, vol.41, pp.1282-1291, 2014.

T. J. Doyle, P. F. Dellaripa, K. Batra, M. L. Frits, C. K. Iannaccone et al., Functional Impact of a Spectrum of Interstitial Lung Abnormalities in Rheumatoid Arthritis, Chest, vol.146, p.41, 2014.

T. Jonsson, H. Thorsteinsson, S. Arinbjarnarson, J. Thorsteinsson, and H. Valdimarsson, Clinical implications of IgA rheumatoid factor subclasses, Ann Rheum Dis, vol.54, pp.578-81, 1995.

J. V. Dunne, D. A. Carson, H. L. Spiegelberg, M. A. Alspaugh, and J. H. Vaughan, IgA rheumatoid factor in the sera and saliva of patients with rheumatoid arthritis and Sjogren's syndrome, Ann Rheum Dis, vol.38, pp.161-166, 1979.

K. Müller, P. Oxholm, M. Høsier-madsen, and A. Wiik, Circulating IgA-and IgMrheumatoid Factors in Patients with Primary Sjögren Syndrome: Correlation to Extraglandular Manifestations, Scand J Rheumatol, vol.18, pp.29-31, 1989.

K. Nishimura, D. Sugiyama, Y. Kogata, G. Tsuji, T. Nakazawa et al., Metaanalysis: Diagnostic Accuracy of Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor for Rheumatoid Arthritis, Ann Intern Med, vol.146, p.797, 2007.

H. Visser, L. B. Gelinck, A. H. Kampfraath, F. C. Breedveld, and J. M. Hazes, Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis, Ann Rheum Dis, vol.55, pp.157-61, 1996.

N. Tanaka, J. S. Kim, J. D. Newell, K. K. Brown, C. D. Cool et al., Rheumatoid Arthritis-related Lung Diseases: CT Findings, Radiology, vol.232, pp.81-91, 2004.

C. Turesson, Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years, Ann Rheum Dis, vol.62, pp.722-729, 2003.

P. Juge, R. Borie, C. Kannengiesser, S. Gazal, P. Revy et al., Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis, Eur Respir J, p.49, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01595463

F. Salaffi, M. Carotti, D. Carlo, M. Tardella, M. Giovagnoni et al., High-resolution computed tomography of the lung in patients with rheumatoid arthritis: Prevalence of interstitial lung disease involvement and determinants of abnormalities, Medicine (Baltimore). sept, vol.98, p.17088, 2019.

P. Spagnolo, J. S. Lee, N. Sverzellati, G. Rossi, and V. Cottin, The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease, Arthritis Rheumatol, vol.70, pp.1544-54, 2018.

, Journée mondiale sans tabac 2019 / World No Tabacco Day, vol.16, 2019.

T. Bongartz, C. Nannini, Y. F. Medina-velasquez, S. J. Achenbach, C. S. Crowson et al., Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study, Arthritis Rheum, vol.62, pp.1583-91, 2010.

K. G. Saag, S. Kolluri, R. K. Koehnke, T. A. Georgou, J. W. Rachow et al., Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities, Arthritis Rheum, vol.39, pp.1711-1720, 1996.

G. Koduri, S. Norton, A. Young, N. Cox, P. Davies et al., Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort, Rheumatology, vol.49, pp.1483-1492, 2010.

C. Salliot and D. Van-der-heijde, Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research, Ann Rheum Dis, vol.68, pp.1100-1104, 2009.

J. K. Dawson, Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests, Rheumatology, vol.41, pp.262-269, 2002.

P. Kiely, A. D. Busby, E. Nikiphorou, K. Sullivan, D. A. Walsh et al., Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts, BMJ Open, vol.9, p.28466, 2019.

G. E. Fragoulis, R. Conway, and E. Nikiphorou, Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature

, Rheumatology, vol.58, pp.1900-1906, 2019.

C. Fernández-díaz, S. Castañeda, R. Melero, J. Loricera, F. Ortiz-sanjuán et al., Op0212 Abatacept in Interstitial Lung Disease Associated with Rheumatoid Arthritis. National Multicenter Study of 263 Patients, Ann Rheum Dis, vol.79, pp.132-132, 2020.

H. Lioté, Complications respiratoires des nouveaux traitements de la maladie rhumatoïde, Rev Mal Respir. déc, vol.21, 2004.

P. Juge and P. Dieudé, Pneumopathies interstitielles diffuses au cours de la polyarthrite rhumatoïde, Rev Rhum Monogr, vol.85, pp.153-162, 2018.

A. De-lauretis, S. Veeraraghavan, and E. Renzoni, Review Series: Aspects of Interstitial lung disease: Connective tissue disease-associated interstitial lung disease: How does it differ from IPF? How should the clinical approach differ?, Chron Respir Dis, vol.8, pp.53-82, 2011.

N. Li, H. Hu, G. Wu, and B. Sun, Value of immune factors for monitoring risk of lung cancer in patients with interstitial lung disease, J Int Med Res, vol.47, pp.3344-53, 2019.

D. Assayag, M. Lubin, J. S. Lee, T. E. King, H. R. Collard et al., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease: Predictors of mortality in RA-ILD, Respirology, vol.19, pp.493-500, 2014.

S. J. Pipavath, D. A. Lynch, C. Cool, K. K. Brown, and J. D. Newell, Radiologic and Pathologic Features of Bronchiolitis, Am J Roentgenol, vol.185, pp.354-63, 2005.

A. A. Bankier, D. Fleischmann, R. Mallek, A. Windisch, F. W. Winkelbauer et al., Bronchial wall thickness: appropriate window settings for thin-section CT and radiologic-anatomic correlation, Radiology, vol.199, pp.831-837, 1996.

T. Perez, M. Remy-jardin, and B. Cortet, Airways Involvement in Rheumatoid Arthritis: Clinical, Functional, and HRCT Findings, Am J Respir Crit Care Med, vol.157, pp.1658-65, 1998.

P. Grenier and C. Beigelman-aubry, Sémiologie de l'atteinte bronchique en scanner, J Radiol, vol.18, 2020.

A. U. Wells, K. R. Flaherty, K. K. Brown, Y. Inoue, A. Devaraj et al., Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, doubleblind, placebo-controlled, parallel-group trial, Lancet Respir Med, vol.8, pp.453-60, 2020.